137 related articles for article (PubMed ID: 38426242)
41. [Treatment of primary oligometastatic prostate cancer].
Scharl S; Hadaschik B; Wiegel T; Thomas C
Urologe A; 2021 Dec; 60(12):1527-1533. PubMed ID: 34825936
[TBL] [Abstract][Full Text] [Related]
42. Completeness of Reporting Oligometastatic Disease Characteristics in the Literature and Influence on Oligometastatic Disease Classification Using the ESTRO/EORTC Nomenclature.
Nevens D; Jongen A; Kindts I; Billiet C; Deseyne P; Joye I; Lievens Y; Guckenberger M
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):587-595. PubMed ID: 35738308
[TBL] [Abstract][Full Text] [Related]
43. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.
Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Christiansen H; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M
Eur Urol Focus; 2021 Mar; 7(2):309-316. PubMed ID: 31495759
[TBL] [Abstract][Full Text] [Related]
44. Recurrent oligometastatic transitional cell bladder carcinoma: is there room for radiotherapy?
Augugliaro M; Marvaso G; Ciardo D; Zerini D; Riva G; Rondi E; Vigorito S; Comi S; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Neoplasma; 2019 Jan; 66(1):160-165. PubMed ID: 30509099
[TBL] [Abstract][Full Text] [Related]
45. Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe.
Kroese TE; van Hillegersberg R; Schoppmann S; Deseyne PRAJ; Nafteux P; Obermannova R; Nordsmark M; Pfeiffer P; Hawkins MA; Smyth E; Markar S; Hanna GB; Cheong E; Chaudry A; Elme A; Adenis A; Piessen G; Gani C; Bruns CJ; Moehler M; Liakakos T; Reynolds J; Morganti A; Rosati R; Castoro C; D'Ugo D; Roviello F; Bencivenga M; de Manzoni G; Jeene P; van Sandick JW; Muijs C; Slingerland M; Nieuwenhuijzen G; Wijnhoven B; Beerepoot LV; Kolodziejczyk P; Polkowski WP; Alsina M; Pera M; Kanonnikoff TF; Nilsson M; Guckenberger M; Monig S; Wagner D; Wyrwicz L; Berbee M; Gockel I; Lordick F; Griffiths EA; Verheij M; van Rossum PSN; van Laarhoven HWM;
Eur J Cancer; 2022 Mar; 164():18-29. PubMed ID: 35134666
[TBL] [Abstract][Full Text] [Related]
46. The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review.
Le Guevelou J; Sargos P; Siva S; Ploussard G; Ost P; Gillessen S; Zilli T
Eur Urol Focus; 2023 Jan; 9(1):114-124. PubMed ID: 36151031
[TBL] [Abstract][Full Text] [Related]
47. Clinical response to induction chemotherapy predicts improved survival outcome in urothelial carcinoma with clinical lymph nodal metastasis treated by consolidative surgery.
Urakami S; Yuasa T; Yamamoto S; Sakura M; Tanaka H; Hayashi T; Uehara S; Inoue Y; Fujii Y; Masuda H; Fukui I; Yonese J
Int J Clin Oncol; 2015 Dec; 20(6):1171-8. PubMed ID: 25953680
[TBL] [Abstract][Full Text] [Related]
48. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
Ost P; Reynders D; Decaestecker K; Fonteyne V; Lumen N; De Bruycker A; Lambert B; Delrue L; Bultijnck R; Claeys T; Goetghebeur E; Villeirs G; De Man K; Ameye F; Billiet I; Joniau S; Vanhaverbeke F; De Meerleer G
J Clin Oncol; 2018 Feb; 36(5):446-453. PubMed ID: 29240541
[TBL] [Abstract][Full Text] [Related]
49. Impact of Baseline Characteristics on the Survival Benefit of High-Intensity Local Treatment in Metastatic Urothelial Carcinoma of the Bladder.
Vetterlein MW; Karabon P; Dalela D; Jindal T; Sood A; Seisen T; Trinh QD; Menon M; Abdollah F
Eur Urol Focus; 2018 Jul; 4(4):568-571. PubMed ID: 28753834
[TBL] [Abstract][Full Text] [Related]
50. Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy.
Devos G; Berghen C; Van Eecke H; Stichele AV; Van Poppel H; Goffin K; Mai C; De Wever L; Albersen M; Everaerts W; De Meerleer G; Joniau S
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32823690
[TBL] [Abstract][Full Text] [Related]
51. Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study.
Kroese TE; Christ SM; van Rossum PSN; Burger MDL; Buijs GS; Mühlematter U; Andratschke N; Ruurda JP; Hüllner M; Gutschow CA; van Hillegersberg R; Guckenberger M
Radiother Oncol; 2022 Aug; 173():269-276. PubMed ID: 35753555
[TBL] [Abstract][Full Text] [Related]
52. Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent.
Buglione M; Jereczek-Fossa BA; Bonù ML; Franceschini D; Fodor A; Zanetti IB; Gerardi MA; Borghetti P; Tomasini D; Di Muzio NG; Oneta O; Scorsetti M; Franzese C; Romanelli P; Catalano G; Dell'Oca I; Beltramo G; Ivaldi GB; Laudati A; Magrini SM; Antognoni P;
Lung Cancer; 2020 Mar; 141():1-8. PubMed ID: 31926440
[TBL] [Abstract][Full Text] [Related]
53. Classifying Oligometastatic Non-Small Cell Lung Cancer.
Blumenthaler AN; Antonoff MB
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638306
[TBL] [Abstract][Full Text] [Related]
54. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
[TBL] [Abstract][Full Text] [Related]
55. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
56. Association Between Local Radiation Therapy to the Primary Bladder Tumor and Overall Survival for Patients with Metastatic Urothelial Cancer Receiving Systemic Chemotherapy.
Fischer-Valuck BW; Patel SA; Brenneman RJ; Christodouleas J; Sargos P; Kim E; Weiss A; Hershatter B; Rao YJ; Picus J; Roth B; Arora V; Carmona R; Reimers M; Zaghloul MS; Gay H; Michalski JM; Baumann BC
Eur Urol Oncol; 2022 Apr; 5(2):246-250. PubMed ID: 35249864
[TBL] [Abstract][Full Text] [Related]
57. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.
Collen C; Christian N; Schallier D; Meysman M; Duchateau M; Storme G; De Ridder M
Ann Oncol; 2014 Oct; 25(10):1954-1959. PubMed ID: 25114022
[TBL] [Abstract][Full Text] [Related]
58. Oligometastatic head and neck cancer: Which patients benefit from radical local treatment of all tumour sites?
Weissmann T; Höfler D; Hecht M; Semrau S; Haderlein M; Filimonova I; Frey B; Bert C; Lettmaier S; Mantsopoulos K; Iro H; Fietkau R; Putz F
Radiat Oncol; 2021 Mar; 16(1):62. PubMed ID: 33789725
[TBL] [Abstract][Full Text] [Related]
59. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis.
Hong JC; Ayala-Peacock DN; Lee J; Blackstock AW; Okunieff P; Sung MW; Weichselbaum RR; Kao J; Urbanic JJ; Milano MT; Chmura SJ; Salama JK
PLoS One; 2018; 13(4):e0195149. PubMed ID: 29649281
[TBL] [Abstract][Full Text] [Related]
60. Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial.
Trovo M; Furlan C; Polesel J; Fiorica F; Arcangeli S; Giaj-Levra N; Alongi F; Del Conte A; Militello L; Muraro E; Martorelli D; Spazzapan S; Berretta M
Radiother Oncol; 2018 Jan; 126(1):177-180. PubMed ID: 28943046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
